ACIU (ACIU) Stock Price & Analysis
ACIU (ACIU) rose 3.20% to USD 2.26 as of June 10, 2026 at 03:12 UTC, according to Nexqual real-time market data.
ACIU last closed at USD 2.19; the session ranged USD 2.1–2.27 on volume of 575,647 shares. Market capitalization is $230.01M, with a 52-week range of USD 1.65–4 (NGM). Source: Nexqual, June 10, 2026 at 03:12 UTC.
Key Statistics (as of June 10, 2026 at 03:12 UTC)
| Price | USD 2.26 |
|---|---|
| Change | ▲ 3.20% (up) |
| Previous Close | USD 2.19 |
| Open | USD 2.19 |
| Day Range | USD 2.1 – 2.27 |
| 52-Week Range | USD 1.65 – 4 |
| Volume | 575,647 shares |
| Market Cap | $230.01M |
| Exchange | NGM |
Technical Analysis (ACIU)
Nexqual's technical model rates ACIU "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.71 (oversold) |
| vs SMA50 | Below (USD 2.85) |
| MACD | -0.17 (negative) |
Analyst Ratings (ACIU)
Wall Street analysts rate ACIU "None" based on 4 analysts, with a mean price target of USD 8.8 (range USD 6.87–11.71), per Nexqual as of June 10, 2026 at 03:12 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 8.8 |
| High Target | USD 11.71 |
| Low Target | USD 6.87 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (ACIU)
| Next Earnings Date | 2026-04-30 |
|---|---|
| EPS Estimate | USD 0.04 |
| Revenue Estimate | $19.30M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.14 ▼ miss |
| 2025-12-31 | USD -0.14 vs est -0.17 ▲ beat |
| 2025-09-30 | USD -0.16 vs est -0.17 ▲ beat |
| 2025-06-30 | USD -0.21 vs est -0.16 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:12 UTC.
Financials & Fundamentals (ACIU)
| Total Revenue | $3.70M |
|---|---|
| Revenue Growth (YoY) | +13.00% |
| Gross Margin | +0.00% |
| Operating Margin | -1321.54% |
| Profit Margin | +0.00% |
| ROE | -104.83% |
| Debt / Equity | 13.65 |
| Current Ratio | 0.87 |
| Total Cash | $74.80M |
| Total Debt | $4.30M |
Source: Nexqual, June 10, 2026 at 03:12 UTC.
Financial Health Score (ACIU)
Nexqual rates ACIU's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:12 UTC.
| Growth | Critical — Revenue -87% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $75M cash vs $4M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -105%, ROA -23.1% |
Ownership (ACIU)
| Insider Ownership | +37.87% |
|---|---|
| Institutional Ownership | +24.83% |
| Shares Outstanding | 101.77M |
| Float | 38.71M |
| Short % of Float | +6.87% |
Source: Nexqual, June 10, 2026 at 03:12 UTC.
Leadership (ACIU)
ACIU is led by Christopher Roberts (age 35), CFO & VP of Finance, per Nexqual as of June 10, 2026 at 03:12 UTC.
| CFO & VP of Finance | Christopher Roberts (age 35) |
|---|---|
| Chief Operating Officer | Piergiorgio Donati (age 54) |
| Senior Vice President of Regulatory Affairs & Quality Assurance | Julien Rongere (age 47) |
| Executive Vice President of Information Systems & Artificial Intelligence | Mark Danton (age 61) |
Major Backers & Investors (ACIU)
Notable institutional backers of ACIU include BVF Inc., Wells Fargo & Company, Millennium Management, according to Nexqual as of June 10, 2026 at 03:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BVF Inc. | 19.48% |
| Wells Fargo & Company | 0.99% |
| Millennium Management | 0.78% |
| Renaissance Technologies | 0.61% |
| Arrowstreet Capital, Limited Partnership | 0.4% |
| Citadel | 0.26% |
| Marshall Wace LLP | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.98% |
| Dimensional Fund Advisors | 0.43% |
| Northern Trust | 0.27% |
Source: Nexqual, June 10, 2026 at 03:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| ACRS | Aclaris Therapeutics, Inc. | USD 4.3 | ▼ 1.38% |
| ALEC | Alector, Inc. | USD 1.63 | ▼ 0.31% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:12 UTC. This page is informational and not investment advice.